- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
InspireMD Announces Distribution Agreement in Portugal
InspireMD announced it has signed an agreement with Medicinália Cormédica MC Medical Lda, a medical distributor in Portugal, to distribute CGuard EPS.
InspireMD (NYSE:NSPR) announced it has signed an agreement with Medicinália Cormédica MC Medical Lda, a medical distributor in Portugal, to distribute CGuard EPS.
As quoted in the press release:
Medicinália Cormédica MC Medical Lda is a subsidiary of WerfenLife Company, one of Europe’s largest distributors of medical products.
Mr. António Cabral, Managing Director of Medicinália Cormédica, noted, “CGuard™ continues to demonstrate its superiority over conventional stents in repeated clinical trials and we look forward to bringing this technology to market in Portugal. Moreover, the clinical data supports the safety and efficacy of carotid artery stenting with CGuard as a minimally invasive alternative to carotid endarterectomy, which further expands the addressable market.”
Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, “The addition of Medicinália Cormédica provides us a strong foothold in Portugal, which represents a new market for CGuard™ EPS.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.